Opioid Usage and Prescribing Predictors Following Transoral Robotic Surgery for Oropharyngeal Cancer
| Autor: | Allen L. Feng, Nicholas B. Abt, Daniel L. Faden, Andrew J Holcomb, Jeremy D. Richmon, Derrick T. Lin, Tara E. Mokhtari, Christopher I McHugh, Anuraag S. Parikh, Mark A. Varvares, Daniel G. Deschler, Krish Suresh |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Overweight 03 medical and health sciences 0302 clinical medicine Robotic Surgical Procedures Internal medicine Transoral robotic surgery medicine Adjuvant therapy Humans Practice Patterns Physicians' 030223 otorhinolaryngology Aged Retrospective Studies Pain Postoperative business.industry Cancer Retrospective cohort study Odds ratio Middle Aged medicine.disease Analgesics Opioid Oropharyngeal Neoplasms Otorhinolaryngology Opioid Chemotherapy Adjuvant 030220 oncology & carcinogenesis Carcinoma Squamous Cell T-stage Female Radiotherapy Adjuvant medicine.symptom business medicine.drug |
| Zdroj: | The Laryngoscope. 131 |
| ISSN: | 1531-4995 0023-852X |
| DOI: | 10.1002/lary.29276 |
| Popis: | OBJECTIVE/HYPOTHESIS Pain management following transoral robotic surgery (TORS) varies widely. We aim to quantify opioid usage following TORS for oropharyngeal squamous cell carcinoma (OPSCC) and identify prescribing predictors. STUDY DESIGN Retrospective cohort study. METHODS A consecutive series of 138 patients undergoing TORS for OPSCC were reviewed from 2016 to 2019. Opioid usage (standardized to morphine milligram equivalents [MME]) was gathered for 12 months post-surgery via prescribing record cross-check with the Massachusetts Prescription Awareness Tool. RESULTS Of 138 OPSCC TORS patients, 92.8% were human papillomavirus (HPV) positive. Adjuvant therapy included radiation (XRT;67.4%) and chemoradiation (cXRT;6.5%). Total MME usage from start of treatment averaged 1395.7 MMEs with 76.4% receiving three prescriptions or less. Categorical analysis showed age |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text